Archive for the ‘Lung Cancer’ Category
Non-Small Cell Lung & Small Cell Lung Cancer Research Trials
Holy Cross Hospital is building a large portfolio of clinical trials for Lung Cancer to make available the latest in therapy for both Non-Small Cell Lung and Small Cell Lung Cancer patients. You can access the trials on our web site and below is the press release that tells you all about our latest Phase 1 trial for Non-Small Cell Lung Cancer.
Holy Cross Hospital Leads in Cancer Research By Enrolling First Patient in International Clinical Trial
Hospital seeks participants with non-small cell lung cancer who have exhausted all other treatment options
FORT LAUDERDALE, Fla. – The Michael and Dianne Bienes Comprehensive Cancer Center at Holy Cross Hospital has enrolled the first patient in what will be the worldwide clinical trial of a new treatment for patients with non-small cell lung cancer (NSCLC) who have exhausted all other options for treatment.
Lung cancer accounts for the most cancer-related deaths in both men and women in the United States. Approximately 87 percent of all lung cancers are non-small cell, a disease in which malignant cells form in the tissues of the lung. Despite medical advances, the five year survival rate for patients diagnosed in any stage of NSCLC is just 15 percent and only 2 percent for those patients whose disease has metastasized and spread outside the lung.
Holy Cross Hospital, which collaborates with Massachusetts General Hospital Cancer Center in Boston to expand oncology services to South Florida residents, is participating in the FDA study of the new investigational drug PF-02341066 that selectively targets cancer-causing genes present in some NSCLC patients.
“Depending on the patient’s age, stage of the disease and overall health, treatments for non-small cell lung cancer can include surgery, radiation therapy, chemotherapy, targeted therapy or a combination of these. In our investigation of this new drug, we are working with patients for whom these standard of care treatments have not been able to stop the growth of their disease,” said Dr. Martin Gutierrez, medical director of the Michael and Dianne Bienes Comprehensive Cancer Center at Holy Cross Hospital.
Eligible patients for the study can be male or female, must be at least 18 years of age and have a proven diagnosis of NSCLC that showed progression after at least one but no more than two chemotherapy regimens. Patients accepted into the study receive the drug orally on a continuous schedule.
Holy Cross Hospital is participating in both Phase One and Phase Two of the trial which is officially titled “Open-Label, Randomized Study of the Safety, Efficacy, and Pharmacokinetics of Erlotinib with or without PF-02341066 in Patients with Advanced Non-Small Cell Adenocarcinoma of the Lung.”
The Holy Cross Hospital Cancer Center offers disease specific care in all oncology sub-specialties including medical, surgical and radiation oncology. The Cancer Center also offers research trials that span from early drug development through the later Phase 3 stages for multiple types of cancer.
Those interested in enrolling in the study or learning more should call the Michael and Dianne Bienes Comprehensive Cancer Center research office at 954-267-7704 or visit www.holycrosscancer.com.
Cancer Research & Treatment FREE Education Program
Cancer patients and survivors, their families, cancer support groups and the public are invited to attend UPDATE 2010: Breast, Lung and Colorectal Cancer Research and Treatment featuring presentations, in non-technical language, by a panel of distinguished cancer experts from Holy Cross Hospital and the Michael and Dianne Bienes Comprehensive Cancer Center. The event will begin with a complimentary light continental breakfast followed by presentations by the speakers, and a question-answer session with the panelists.
Breast Cancer –Screening and Diagnosis: What Is New and What Is Right?
Joseph Casey, M.D., Breast Surgical Oncologist
New Developments in Breast Cancer Surgery and Breast Reconstruction
Marnie Kaplan, M.D., Holy Cross Hospital, Breast Surgical Oncologist
What Role Does Chemotherapy Play in Breast Cancer Treatment?
Ena Segota, M.D., Holy Cross Hospital, Medical Oncologist/Hematologist
Colorectal Cancer Screening – How Important Is It?
Donald Brust, M.D., Holy Cross Hospital, Gastroenterologist
Surgical Intervention For Colon Cancer: Open Surgery Vs Laparoscopic Surgery
Elie Schochet, M.D., Holy Cross Hospital, Colorectal Surgeon
New Radiation Oncology Advances For Treating Cancer
Lav Goyal, M.D., Holy Cross Hospital, Radiation Oncologist
Lung Cancer – What is State of the Art Care?
Martin Gutierrez, M.D., Holy Cross Hospital, Medical Oncologist/Hematologist
Developing New Cancer Drugs and Clinical Trials for Lung Cancer
Martin Gutierrez, M.D., Holy Cross Hospital, Medical Oncologist/Hematologist
Carol Brudenell, RN, AOCN, Holy Cross Hospital, Research Manager
Q&A Panel
Saturday, March 27, 2010 • 8:30 am – 12:30 pm
Holy Cross Hospital
4725 North Federal Highway
Fort Lauderdale, Florida 33308
Sister Innocent Conference Center
This program is jointly sponsored by Holy Cross Hospital’s Michael and Dianne Bienes Comprehensive Cancer Center and the Syncure Cancer Research Foundation as a public service for cancer patients and their families.
Admission to the program is FREE with advanced registration. Please register early; seating is limited!
To register or for additional information, please contact Holy Cross Hospital:
Toll-Free: 800-903-9702 / Web Address: www.holy-cross.com
2009 Recap
How quickly this year has passed! It is hard for us to believe that this is the last blog post for our first year on the blogging circuit! We have enjoyed bringing this new venue of information and communication to you – our cancer center patients and interested community – and we hope that you have found it to be valuable too!.
It has been quite a busy and productive year for us at Holy Cross and the Bienes Cancer Center. We have continued to grow – both in terms of patient volume and size of professional staff. During 2009 we added new subspecialties and sub-specialists to our team including colorectal surgeons – Drs. Lescher, Basu and Schochet and added a new Hematologist/Oncologist Dr. David Drew who joined us in November from the National Cancer Institute. We added new technologies in our radiation oncology department including a new ultrasound based tumor localization system and a brand new linear accelerator with IGRT (Image-guided radiation therapy) and stereotactic radiosurgery capabilities. There is no cancer center in South Florida that has more technology than we do now! And we have maintained our high touch service along with the spirituality and faith based approach that we do with everything at Holy Cross. We continued to develop our disease specific focus for our physicians so that we have dedicated teams of physicians now who focus their practices on breast cancer, prostate cancer, gastrointestinal cancers, lung cancers and colorectal cancers. This specialization is allowing us to be the true leaders in our field that patients deserve and need.
Finally we have significantly expanded our clinical research program – opening the first community hospital based phase 1 clinical trials for cancer in South Florida. We are truly excited to be able to offer these new options to patients who have exhausted all other treatments.
Thank you for participating with us on our journey. 2010 promises to be even more exciting!
Holy Cross Current Lung Cancer Clinical Trial List
This is an incredibly exciting time in our cancer center. Under Dr. Martin Gutierrez’ leadership our clinical research program is soaring to new heights. We have now opened numerous clinical trials for our enhanced lung cancer program. You will begin to see print ads, direct mailings and also hear ads on the radio to educate people about what new treatment options are available to certain cancer patients.
Listed below is a few of the trials in the Holy Cross Hospital Lung Clinical Trial List:
- A Phase III Randomized Trial Of Adjuvant Chemotherapy With Or Without Bevacizumab For Patients With Completely Resected Stage Ib (> 4 Cm) – IIIa Non-Small Cell Lung Cancer (NSCLC)
- The Impact Of Ethnic Origin On Patients Being Treated Second Line With Pemetrexed – An Observational Study
- Phase III Comparison Of Thoracic Radiotherapy Regimens In Patients With Limited Small Cell Lung Cancer Also Receiving Cisplatin And Etoposide
- A Phase II, Randomized, Open Label Study Of Figitumumab Plus Cisplatin (Or Carboplatin) And Etoposide, Versus Cisplatin And Etoposide Alone, As First Line Treatment In Patients With Extensive-Stage Disease Small Cell Lung Cancer
- Phase 1/2, Open-Label, Randomized Study of the Safety, Efficacy, and Pharmacokinetics of Erlotinib with or without PF-02341066 in Patients with Advanced Non-Small Cell Adenocarcinoma of the Lung
- Phase II, open-label single arm study of the efficacy and safety of PF 02341066 in patients with advanced non-small cell lung cancer (NSCLC) harboring a translocation or inversion involving the anaplastic lymphoma kinase (ALK) gene locus
- Phase III, Randomized, Open-Label Study of the Efficacy and Safety of PF-02341066 versus Standard of Care Chemotherapy (Pemetrexed or Docetaxel) in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Harboring a Translocation or Inversion Event Involving the Anaplastic Lymphoma Kinase (ALK) Gene Locus
- Phase II Trial of Preoperative Chemotherapy and Bevacizumab in Patients with Stage IB (>4 cm), II, or Select Stage III Non-Small Cell Lung Cancer
- Phase II trial for Stage IIIB/IV Non-Small Lung Cancer (NSCLC) with three arm chemotherapy study for Poor Performance Status patients
- Phase 1b/II Study to Determine the Recommended Dose, Safety, and Preliminary Efficacy of Belinostat (PXD 101), a Histone Deacytylase Inhibitor, in Combination with Carboplatin, Paclitaxel, and Bevicizumzb (BelcaP-B) in Patients with Untreated Non-small Cell Lung Cancer (NSCLC)
This brings a whole new array of options for patients to be treated. If you are interested in learning more please call me at 954-267-7704. If you know of a patient who may be eligible for one of these trials please call our lung cancer program line at 954-351-LUNG (5864) to schedule an appointment to see Dr. Gutierrez.
More next month.
About the Center
The Michael & Dianne Bienes Comprehensive Cancer Center in Fort Lauderdale, Florida is the Cancer Care Leader in Broward County. Dedicated to providing patients with precise diagnosis, the latest and most advanced treatment and aftercare options, we offer a multidisciplinary approach to care, a compassionate and spiritual healing environment, and an affiliation with the National Cancer Institute. We are also working together with Massachusetts General Hospital Cancer Center to provide South Florida residents with rapid access to specialized cancer care and genetics counseling.
Browse by Category
- Breast Cancer Surgery (14)
- Cancer Support (24)
- Gastrointestinal Cancer (4)
- General Medical (28)
- Lung Cancer (10)
- Nutrition (2)
- Prostate Cancer (5)
- Radiation (11)
- Research and Genetics (21)
- Spirituality (20)